Nirmatrelvir and Ritonavir are used together to treat COVID-19 (Coronavirus disease). How Nirmatrelvir + Ritonavir Work This combination includes two medications: • Nirmatrelvir, which is a SARS-CoV-2-3CL protease inhibitor that blocks an enzyme the virus needs to multiply. • Ritonavir, originally used to treat HIV, helps boost the effect of nirmatrelvir by slowing its breakdown in the body. Together, they help reduce the ability of the virus to spread and cause infection. Uses of Paxista (Nirmatrelvir 150mg + Ritonavir 100mg Tablet): Paxista is used for the treatment of mild to moderate COVID-19 infections in adults and adolescents who are at high risk of developing severe COVID-related complications, including hospitalization or death. It is most effective when administered within 5 days of the onset of symptoms, allowing early intervention to suppress viral replication and prevent disease progression. The combination works in two key ways: Nirmatrelvir targets the SARS-CoV-2 main protease enzyme (Mpro), which is essential for the replication of the virus. By inhibiting this enzyme, it halts the virus from multiplying within the body. Ritonavir, although originally developed for HIV treatment, is used here as a pharmacokinetic booster. It increases the effectiveness of Nirmatrelvir by slowing its breakdown in the body, maintaining higher active drug levels for longer periods. Paxista is especially useful for individuals with underlying health conditions such as: -Diabetes -Heart disease -Chronic lung conditions (like asthma or COPD) -Kidney disease -Weakened immune systems due to age, illness, or medications